Role of a signaling pathway in feline injection site sarcoma

Feline injection sites sarcomas (FISS) are malignant entities derived from the mesenchymal origin. Activation of nuclear factor-kappa B (NF-κB) signaling pathway has been documented being able to target genes associated with tumor progression in several human solid tumors.

Researchers evaluated primary cells derived from FISS and the effects of the NF-κB inhibitor on primary tumor cells were conducted.

In the study, nuclear expression of NF-κB p65 was detected in 83.3% of FISS cases. There was no correlation between tumor grading, sex, or age. The NF-κB inhibitor was able to prevent nuclear translocation of NF-κB p65, inhibit cell proliferation, migration, and colonization in dosage-dependent manners, and induce cell apoptosis in these primary FISS cells.

Read more by clicking on the link below:

Role of nuclear factor-kappa B in feline injection site sarcoma.